Duquesne Family Office’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $268M | Buy |
15,968,935
+1,089,185
| +7% | +$18.3M | 6.57% | 2 |
|
|
2025
Q1 | $229M | Buy |
14,879,750
+5,882,350
| +65% | +$90.4M | 7.47% | 2 |
|
|
2024
Q4 | $198M | Buy |
8,997,400
+7,569,450
| +530% | +$167M | 5.33% | 4 |
|
|
2024
Q3 | $25.7M | Buy |
+1,427,950
| New | +$25.7M | 0.87% | 23 |
|
|
2015
Q2 | – | Sell |
-790,500
| Closed | -$49.2M | – | 43 |
|
|
2015
Q1 | $49.2M | Buy |
+790,500
| New | +$49.2M | 6.26% | 6 |
|
|
2014
Q3 | – | Sell |
-1,241,000
| Closed | -$65.1M | – | 61 |
|
|
2014
Q2 | $65.1M | Hold |
1,241,000
| – | – | 4.64% | 6 |
|
|
2014
Q1 | $65.6M | Hold |
1,241,000
| – | – | 7.4% | 4 |
|
|
2013
Q4 | $49.7M | Buy |
+1,241,000
| New | +$49.7M | 3.31% | 8 |
|